Valsartan Sacubitril

CAS 936623-90-4

General Information

The combination of valsartan and sacubitril constitutes a novel strategy to reduce the risk of death and hospitalization due to heart failure. It is used in patients with chronic heart failure and reduced ejection fraction for almost all severity levels of heart failure (except for the lowest, level I, by New York Heart Association Functional Classification). Ejection fraction is a measurement for assessing the heart’s ability to pump out blood and for diagnosing and monitoring heart failure.

About the API

Systematic name Octadecasodiumhexakis(4-{[(1S,3R)-1-([1,1´-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)hexakis(N-pentanoyl-N-{[2´-(1H-tetrazol-1-id-5-yl)[1,1´-biphenyl]-4-yl]methyl}-L-valinate)—water (1/15).
Trade name(s) Entresto, LCZ696
Technology Synthetic
Molecular Formula C48H55N6O8Na3 2.5 H2O
Molecular Weight 957.99 g/mol
Physical properties White to almost white crystalline powder
Therapeutic category Cardiovascular
Available formulations Oral Solid
Regulations US DMF Flag US DMF